| CERITINIB | Small molecule | cancer | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Withdrawn | ClinicalTrials |
| CRIZOTINIB | Small molecule | anaplastic large cell lymphoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 4.0 | Unknown status | ClinicalTrials |
| CRIZOTINIB | Small molecule | multiple myeloma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Active, not recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Terminated | ClinicalTrials |
| CRIZOTINIB | Small molecule | neoplasm | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 3.0 | Active, not recruiting | ClinicalTrials |
| CERITINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 3.0 | Active, not recruiting | ClinicalTrials |
| CERITINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Completed | ClinicalTrials |
| CRIZOTINIB | Small molecule | neoplasm | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Recruiting | ClinicalTrials |
| CERITINIB | Small molecule | neoplasm | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Terminated | ClinicalTrials |
| CRIZOTINIB | Small molecule | kidney disease | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Completed | ClinicalTrials |
| CERITINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Terminated | ClinicalTrials |
| CRIZOTINIB | Small molecule | diffuse large B-cell lymphoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 4.0 | - | DailyMed |
| CERITINIB | Small molecule | inflammatory myofibroblastic tumor | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Terminated | ClinicalTrials |
| CERITINIB | Small molecule | pancreatic adenocarcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Completed | ClinicalTrials |
| CRIZOTINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 4.0 | - | DailyMed |
| CRIZOTINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 3.0 | Completed | ClinicalTrials |
| CRIZOTINIB | Small molecule | inflammatory myofibroblastic tumor | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 4.0 | Recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | lymphoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 4.0 | Withdrawn | ClinicalTrials |
| CRIZOTINIB | Small molecule | prostate cancer | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Completed | ClinicalTrials |
| CRIZOTINIB | Small molecule | inflammatory myofibroblastic tumor | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Unknown status | ClinicalTrials |
| CRIZOTINIB | Small molecule | anaplastic large cell lymphoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 4.0 | Recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | endometrial cancer | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | squamous cell carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Active, not recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | breast cancer | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Terminated | ClinicalTrials |
| CERITINIB | Small molecule | soft tissue sarcoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 3.0 | Recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | cancer | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | papillary renal cell carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Active, not recruiting | ClinicalTrials |
| CERITINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Completed | ClinicalTrials |
| CRIZOTINIB | Small molecule | adenocarcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Completed | ClinicalTrials |
| CRIZOTINIB | Small molecule | metastatic malignant neoplasm | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Active, not recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | neoplasm | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 4.0 | - | ATC |
| CRIZOTINIB | Small molecule | colorectal carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Completed | ClinicalTrials |
| CRIZOTINIB | Small molecule | neoplasm | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Completed | ClinicalTrials |
| CRIZOTINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Unknown status | ClinicalTrials |
| CRIZOTINIB | Small molecule | cancer | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Completed | ClinicalTrials |
| CRIZOTINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 3.0 | Active, not recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Terminated | ClinicalTrials |
| CERITINIB | Small molecule | melanoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Active, not recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | neoplasm | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Not yet recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | glioblastoma multiforme | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Completed | ClinicalTrials |
| CERITINIB | Small molecule | liver disease | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Completed | ClinicalTrials |
| CERITINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Active, not recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 3.0 | Recruiting | ClinicalTrials |
| CERITINIB | Small molecule | melanoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Recruiting | ClinicalTrials |
| CERITINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Active, not recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Withdrawn | ClinicalTrials |
| CRIZOTINIB | Small molecule | gastric cancer | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Completed | ClinicalTrials |
| CERITINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 4.0 | - | DailyMed |
| CRIZOTINIB | Small molecule | acute myeloid leukemia | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Recruiting | ClinicalTrials |
| CERITINIB | Small molecule | anaplastic large cell lymphoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Terminated | ClinicalTrials |
| CRIZOTINIB | Small molecule | lung cancer | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Completed | ClinicalTrials |
| CRIZOTINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Completed | ClinicalTrials |
| CERITINIB | Small molecule | thyroid cancer | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Withdrawn | ClinicalTrials |
| CRIZOTINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Completed | ClinicalTrials |
| CERITINIB | Small molecule | neoplasm | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Completed | ClinicalTrials |
| CRIZOTINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Active, not recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | lung adenocarcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 3.0 | Recruiting | ClinicalTrials |
| CERITINIB | Small molecule | neuroblastoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | diffuse intrinsic pontine glioma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Completed | ClinicalTrials |
| CERITINIB | Small molecule | anaplastic large cell lymphoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Withdrawn | ClinicalTrials |
| CRIZOTINIB | Small molecule | neurofibromatosis type 2 | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Active, not recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | lung adenocarcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Unknown status | ClinicalTrials |
| CRIZOTINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 3.0 | Not yet recruiting | ClinicalTrials |
| CERITINIB | Small molecule | neoplasm | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 4.0 | - | ATC,DailyMed |
| CERITINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Active, not recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | cancer | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Terminated | ClinicalTrials |
| CRIZOTINIB | Small molecule | Uveal Melanoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Active, not recruiting | ClinicalTrials |
| CERITINIB | Small molecule | cancer | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 4.0 | Recruiting | ClinicalTrials |
| CERITINIB | Small molecule | cutaneous melanoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Terminated | ClinicalTrials |
| CRIZOTINIB | Small molecule | neoplasm | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Active, not recruiting | ClinicalTrials |
| CERITINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Unknown status | ClinicalTrials |
| CRIZOTINIB | Small molecule | anaplastic large cell lymphoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Active, not recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | lung adenocarcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Terminated | ClinicalTrials |
| CRIZOTINIB | Small molecule | adenocarcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Active, not recruiting | ClinicalTrials |
| CRIZOTINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 4.0 | Recruiting | ClinicalTrials |
| CERITINIB | Small molecule | cholangiocarcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Terminated | ClinicalTrials |
| CRIZOTINIB | Small molecule | metastatic malignant neoplasm | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1.0 | Completed | ClinicalTrials |
| CERITINIB | Small molecule | glioblastoma multiforme | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Terminated | ClinicalTrials |
| CRIZOTINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 0.5 | Withdrawn | ClinicalTrials |
| CERITINIB | Small molecule | non-small cell lung carcinoma | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 2.0 | Terminated | ClinicalTrials |